The Weekly Recap 5/1/26: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni receive regulatory approvals, secure funding, launch partnerships, and much more on the road to LSI Asia ‘26 in Singapore (June 30 - July 2).

Avatar Medical

Received FDA 510(k) clearance for Avatar Medical Vision, its software platform for instant 3D medical image processing, review, and surgical planning, enabling commercialization in the U.S. This clearance also establishes compatibility with the Barco Eonis 3D glasses-free display, forming the foundation of Eonis Vision, a joint solution that aims to bring clinicians and patients together around a shared, real-time view of anatomy during consultations.

Axoft

Raised an oversubscribed $55M Series A led by C.P. Group Innovation, with participation from Alumni Ventures, the Stanford President’s Venture Fund, Hillhouse Investment, and Gaorong Ventures. The company will use the funds to expand global clinical trials, advance U.S. regulatory approval of its implantable brain-computer interfaces, and build a GMP facility for large-scale production.

BrightHeart

Appointed Jeff Barone as its VP of Sales, U.S., to lead U.S. commercial strategy and execution. Barone brings an extensive track record of executive leadership across imaging, medtech, minimally invasive surgical technologies, and robotic platforms.

Circular Genomics & Vitazi.AI

Announced a strategic alliance to jointly develop a next-generation multimodal workflow for the early detection and risk stratification of Alzheimer's disease. The collaboration will combine Vitazi.ai's non-invasive, AI-driven retinal imaging analytics with Circular Genomics' proprietary circRNA biomarker data, leveraging shared algorithmic and machine learning workflows to deliver intelligent, accurate early detection of Alzheimer’s and risk stratification.

CorFlow

Successfully completed Phase 1 of its MOCA II FDA Pivotal Trial and enrolled the first patients for Phase 2 of the trial while simultaneously gaining approval to enroll patients in its parallel flagship clinical trial, the novel randomized REVITALISE trial. The company also welcomed Dr. Rick Kuntz to its Board of Directors and appointed LSI Alumni Dr. Pedro Eerdmans as VP Clinical.

CorTec

Announced that the first participant in the University of Washington’s NIH-funded clinical trial of the Brain Interchange™ BCI system has successfully controlled a computer through thought alone, including a functional demonstration of the video game Pong, using the implanted device and cortical electrodes placed to support his motor recovery after stroke. This is the first reported instance worldwide in which a single fully implanted, wireless BCI system has demonstrated both brain stimulation for therapeutic stroke rehabilitation enhancement and thought-based computer control in the same patient using identical hardware.

CorVista Health

Announced a research collaboration with Mayo Clinic to evaluate how next-generation, non-invasive diagnostics may transform the identification and management of pulmonary hypertension. The collaboration will pair the FDA-cleared CorVista-PH test, part of the CorVista System, with Mayo Clinic’s expertise in cardiovascular research and pulmonary vascular disease to determine whether the CorVista-PH test can meaningfully improve how physicians identify and evaluate pulmonary hypertension earlier in the patient journey.

FluidAI Medical & Qaelon Medical

Announced a strategic collaboration to develop a continuous surgical data ecosystem spanning the operating room through recovery, with a focus on addressing anastomotic leaks in gastrointestinal surgery. The partnership combines Qaelon’s intraoperative leak detection platform with FluidAI’s established post-operative monitoring and intelligence ecosystem, and aims to create a unified framework linking intraoperative data with post-operative healing to improve patient outcomes and reduce complications.

Hypervision Surgical

Closed an oversubscribed $23M Series A financing round led by Heal Capital, with participation from Angelini Ventures, IP Group, Daycrest, and follow-on investment from Heran Partners, Redalpine, LifeX Ventures, and Zeiss Ventures. The company plans to use the funds to accelerate commercial deployment of its Hyperspectral Intelligence® platform, expand clinical adoption, and advance next-generation hyperspectral sensing technology in partnership with Imec.

This blog is originally published here: https://www.lifesciencemarketresearch.com/insights/the-weekly-recap-5126-lsi-alumni-achievements-driving-medtech-and-healthtech-forward

Comments

Post a Comment

Popular posts from this blog

Cover Story: A Page from Ray Cohen’s Playbook: Scaling, Exiting, and Winning in Medtech

With four decades of company-building, IPOs, boardroom leadership, and monumental exits behind him, Raymond W. Cohen has become one of medtech’s most successful operators. But behind the financial wins — including the recent back-to-back $3.7 billion Axonics and $600 million SoniVie acquisitions by Boston Scientific — is a deeper story of Cohen’s contrarian, full-transparency, people-centered, no-BS approach to leadership and strategy. “People crave inspired, authentic, and transparent leadership that thinks big and acts boldly. They want to be enrolled in a vision of what is possible, and be recognized and compensated for creating measurable results, not be fed a bunch of platitudes.” A quote that is classic  Ray Cohen  — blunt, unapologetic, no-nonsense, and grounded in hard-won experience. With more than four decades in medtech, Cohen has done what many aspire to — build, lead, scale, and sell high-stakes, successful ventures with precision and zero fluff. Known for his no-...
Read more

The Weekly Recap 6/13/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $63M in new funds, receive FDA 510(k) clearances, announce an acquisition, and much more as we wind down   LSI Asia  ’25 in Singapore and gear up for  LSI Europe  ’25 in London (September 7–11). Accelus Received FDA 510(k) clearance for the FlareHawk Interbody Fusion System to be safely subjected to MRI scanning in certain conditions. The clearance supports Accelus’s commitment to safe, high-performance spinal solutions and expands imaging options for patients with FlareHawk implants. Aortyx Raised $16M to advance its bioresorbable aortic patch toward first-in-human trials. The funding supports continued development of Aortyx’s minimally invasive, tissue-regenerating solution for aortic dissection and positions the company for clinical entry within two years. Atraverse Medical Closed $29.4M in follow-on financing to scale U.S. commercialization of HOTW...
Read more

Microbot Medical and the Endovascular Robotics Opportunity Taking Shape

In November, Microbot Medical reached a meaningful milestone in the evolution of endovascular robotics, announcing that Emory University Hospital in Atlanta has become the first hospital worldwide to use the company’s LIBERTY system for patient care. Microbot is currently operating under a limited commercial release following FDA clearance, with a broader market launch planned for April 2026 at the Society of Interventional Radiology conference. While still early, the move signals growing confidence that robotic assistance inside the vasculature is beginning to transition from concept to clinical reality. To understand why this matters, it helps to step back and examine the numbers behind the endovascular robotics market and how Microbot’s approach fits into a rapidly evolving competitive landscape. Defining the Endovascular Procedure Landscape Endovascular procedures encompass any intervention performed from within a blood vessel. In practical terms, this includes coronary, periphe...
Read more